1.19
-0.05 (-3.87%)
| Previous Close | 1.24 |
| Open | 1.21 |
| Volume | 5,576 |
| Avg. Volume (3M) | 126,706 |
| Market Cap | 41,036,216 |
| Price / Earnings (Forward) | 20.33 |
| Price / Book | 731.49 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -0.110 |
| Total Debt/Equity (MRQ) | 6.71% |
| Current Ratio (MRQ) | 1.91 |
| Operating Cash Flow (TTM) | -4.91 M |
| Levered Free Cash Flow (TTM) | -3.52 M |
| Return on Assets (TTM) | -99.87% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Jupiter Neurosciences, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -2.5 |
| Average | -0.88 |
|
Jupiter Neurosciences Inc is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The company has developed a unique resveratrol platform product primarily targeting treatment of neuro-inflammation. Its platform product, JOTROL, offers potential therapeutic benefit to most central nervous system diseases such as Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 57.50% |
| % Held by Institutions | 1.17% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Vestor Capital, Llc | 30 Sep 2025 | 970,985 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Dec 2025 | Announcement | Jupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial Momentum |
| 02 Dec 2025 | Announcement | Jupiter Neurosciences to Participate in NobleCon21 |
| 06 Nov 2025 | Announcement | Jupiter Neurosciences Brings Its Brain Health Expertise To The Masses With Nugevia - And A Range Of Celebs From Athletes To Scientists Are Customers |
| 05 Nov 2025 | Announcement | Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease |
| 27 Oct 2025 | Announcement | Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing |
| 15 Sep 2025 | Announcement | Jupiter Neurosciences Names Visionary Entrepreneur and Biohacker Jean Fallacara as Third Nugevia™ Brand Ambassador |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |